Cardinal Health (NYSE:CAH – Get Free Report) had its price objective increased by equities researchers at JPMorgan Chase & Co. from $215.00 to $260.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 12.12% from the company’s current price.
A number of other research analysts have also issued reports on the stock. Mizuho boosted their target price on shares of Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday. William Blair initiated coverage on Cardinal Health in a report on Tuesday, April 28th. They set an “outperform” rating on the stock. UBS Group boosted their price objective on Cardinal Health from $274.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird increased their price objective on Cardinal Health from $251.00 to $274.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Barclays raised their target price on Cardinal Health from $258.00 to $275.00 and gave the company an “overweight” rating in a research report on Thursday. Fifteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $265.60.
Get Our Latest Stock Analysis on Cardinal Health
Cardinal Health Stock Down 1.0%
Cardinal Health (NYSE:CAH – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. The business had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.74%. The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, equities research analysts expect that Cardinal Health will post 12.5 EPS for the current fiscal year.
Hedge Funds Weigh In On Cardinal Health
Hedge funds have recently made changes to their positions in the business. Investors Research Corp bought a new stake in Cardinal Health during the second quarter worth approximately $29,000. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cardinal Health in the fourth quarter valued at $26,000. Allied Private Wealth LLC bought a new position in shares of Cardinal Health in the second quarter valued at $30,000. Bank of Jackson Hole Trust bought a new stake in shares of Cardinal Health during the 4th quarter worth $27,000. Finally, Indiana Trust & Investment Management Co acquired a new stake in shares of Cardinal Health during the first quarter worth $29,000. Institutional investors and hedge funds own 87.17% of the company’s stock.
Trending Headlines about Cardinal Health
Here are the key news stories impacting Cardinal Health this week:
- Positive Sentiment: Earnings and outlook: Fiscal fourth-quarter adjusted EPS of $2.91 exceeded estimates by $0.49, while management projected 13%–15% fiscal 2027 EPS growth. Strength in pharmaceutical distribution, specialty products, At-Home Solutions and medical technology supported the outlook. CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
- Positive Sentiment: Analyst target increases: Citigroup raised its target to $280 with a Buy rating, Wells Fargo lifted its target to $277 with an Overweight rating, and Baird increased its target to $274 with an Outperform rating. The revisions reflect confidence in earnings growth and execution. Cardinal Health Analysts Increase Their Forecasts Following Q4 Results
- Positive Sentiment: Capital returns and strategic momentum: Cardinal Health expanded its share-repurchase authorization, while its 29-year dividend-growth streak and nearly doubled medical-technology profit provide additional support for shareholders. Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
- Neutral Sentiment: Dividend maintained: The company declared a quarterly dividend of $0.5158 per share, payable October 15, equivalent to an annualized yield of approximately 0.9%. The payout reinforces income and capital-return appeal but is modest relative to the share price.
- Negative Sentiment: Revenue miss and valuation risk: Quarterly revenue of $63.67 billion fell short of the $65.15 billion consensus estimate. After the stock’s sharp run to an all-time high, investors may be questioning whether strong earnings expectations and the company’s cash-generation story are already reflected in the valuation. Cardinal Health misses Q2 CY2026 sales expectations
Cardinal Health Company Profile
Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.
The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.
Featured Articles
- Five stocks we like better than Cardinal Health
- Axos Financial Keeps Proving the Digital Banking Model Works
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
- Plug Power Charges Ahead: Margin Expansion Sparks a Rally
- Abercrombie’s Comeback Is a Work in Progress
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.
